ArticleEndocrinology2015
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.
Article in Endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.The Journal of clinical endocrinology and metabolism · 2021Trial
- Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.BMC endocrine disorders · 2025Article
- Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.The Journal of clinical endocrinology and metabolism · 2023Article
- The Clinical and Pathological Characteristics of Refractory Pituitary Adenomas: A Single Center Experience.Frontiers in oncology · 2022Article
- Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review.Journal of clinical medicine · 2021Review
- Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?Endocrine pathology · 2021Review
- Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.Frontiers in endocrinology · 2021Review
- Emerging and Novel Treatments for Pituitary Tumors.Journal of clinical medicine · 2019Review
- Prolactin - a pleiotropic factor in health and disease.Nature reviews. Endocrinology · 2019Review
- Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies.European endocrinology · 2019Review
- The Treatment of Refractory Pituitary Adenomas.Frontiers in endocrinology · 2019Review
- Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease.Frontiers in endocrinology · 2018Review
- Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.International journal of molecular sciences · 2017Review
- Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.Current opinion in endocrinology, diabetes, and obesity · 2017Review
- Recent Progress in the Medical Therapy of Pituitary Tumors.Endocrinology and metabolism (Seoul, Korea) · 2017Review
- EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis.Journal of the Endocrine Society · 2017Article
- Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2016Article
- Pituitary tumors.Endocrinology and metabolism clinics of North America · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
As ErbB receptors are expressed in prolactinomas and exhibit downstream effects on prolactin (PRL) production and cell proliferation, we generated transgenic mice using a PRL enhancer/promoter expression system to restrict lactotroph-specific expression of human epidermal growth factor receptor (EGFR) or human EGFR2 (HER2). EGFR or HER2 transgenic mice developed prolactinomas between 13 and 15 months, and confocal immunofluorescence and Western blot analysis confirmed lactotroph-restricted PRL and EGFR or HER2 coexpression. Circulating PRL levels in EGFR and HER2 transgenic mice were increased 5- and 3.8-fold, respectively. Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. This model demonstrates the role of ErbB receptors underlying prolactinoma tumorigenesis and the feasibility of targeting these receptors for translation to treatment of refractory prolactinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.